Department of Surgery »  Faculty »  General Surgery »  David Donner, Ph.D.

David Donner, Ph.D.

Adjunct Professor
Division of General Surgery

Contact Information

1600 Divisadero Street
San Francisco, California 94143-1932
(415) 353-9294
Fax: (415) 353-9296
david.donner@ucsfmedctr.org

Education

  • Queens College, New York, NY, B.A., 1966, Chemistry

Postdoctoral Training

  • Rensselaer Polytechnic Institute, New York, NY, Ph.D., 1972, Chemistry
  • Cornell University, Ithaca, NY, post-doc, 1972-1973, Biochemistry

Program Affiliations

  • Surgical Oncology Program
  • Surgical Oncology Laboratory
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Department of Surgery

Research Interests

  • Coordinate regulation of pro-apoptotic and pro-survival genes
  • Death receptor signaling
  • Inflammation in the initiation and progression of cancer
  • Sall2 transcription factor as a cancer biomarker
  • Tumor suppressor-oncoprotein networks

Biography

Dr. Donner is a molecular-cell biologist in the Surgical Oncology Research Laboratory.  Dr. Donner received his undergraduate degree for Queens College of the City University of New York.  He conducted doctoral research at Rensselaer Polytechnic Institute in the area of chemical evolution and the origins of life on earth.

His studies on chemical evolution contributed to the first Viking probe that searched for life on Mars.  After postdoctoral studies in neurobiology conducted under the mentorship of Dr. George P. Hess at Cornell University, Ithaca New York, Dr. Donner joined the faculty of Cornell University Medical College and the Memorial Sloan Kettering Cancer Center in New York City. There Dr. Donner defined how mitogens, cytokines, and their receptors contribute to cancer.

Dr. Donner served an eight-year term as Director of the Biochemistry and Genetics Division at Sloan-Kettering as well as serving on the Executive Committee of the Institute.  Dr. Donner has also served on numerous Editorial Boards and Grant Review Committees for the National Institutes of Health and as an Editor for "Endocrinology".

Dr. Donner moved from Sloan-Kettering to the Indiana University School of Medicine as Professor of Physiology, Microbiology and Immunology, and a Member of the Indiana University Cancer Center.  Since joining the faculty of UCSF as Professor in Residence in the Department of Surgery and a member of the Helen Diller Comprehensive Cancer Center in 2005, Dr. Donner's laboratory has focused its efforts on identifying and understanding the functions of biomarkers that may predict the course and likelihood of recurrence of human colon cancer.

Dr. Donner is the recipient of numerous awards including the NIH Career Development Award, the American Cancer Society Faculty Research Award,  Louise & Alston Boyer Young Investigator Award for Laboratory Research, American Diabetes Association Research and Development Award, NY State Regents Scholarship, and the NY State Scholar Incentive Award. 

 

Research Overview

Dr. Donner's research is aimed at understanding how derangements in tumor suppressor-oncoprotein signaling networks are permissive of cancer.   Of particular interest is how signaling through "death receptors" may sometimes induce cancer cells to undergo programmed cell death, yet in other instances may promote the aggressive growth and spread of malignancies.  Recently, Dr. Donner's research group identified a novel factor called Sall2 that may act as a molecular switch to determine whether life or death signals predominate downstream of death receptors.   Furthermore, the absence or presence of polymorphic forms of Sall2 appears predictive of whether colon cancer will recur.   Considerable effort is being directed towards determining whether Sall2 may be a clinically useful biomarker that can predict the course of colon cancer and whether the malignancy will be responsive to therapy.   

 

Publications

Most recent publications from a total of 80
  1. Farkas C, Martins CP, Escobar D, Hepp MI, Donner DB, Castro AF, Evan G, Gutiérrez JL, Warren R, Pincheira R. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress. PLoS One. 2013; 8(9):e73817. View in PubMed
  2. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87. View in PubMed
  3. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600. View in PubMed
  4. Schiavi F, Demattè S, Cecchini ME, Taschin E, Bobisse S, Del Piano A, Donner D, Barbareschi M, Manera V, Zovato S, Erlic Z, Savvoukidis T, Barollo S, Grego F, Trabalzini F, Amistà P, Grandi C, Branz F, Marroni F, Neumann HP, Opocher G. The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression. J Clin Endocrinol Metab. 2012 Apr; 97(4):E637-41. View in PubMed
  5. Lin CI, Barletta JA, Nehs MA, Morris ZS, Donner DB, Whang EE, Jeong JW, Kimura S, Moore FD, Ruan DT. Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-?B activity. Surgery. 2011 Dec; 150(6):1295-302. View in PubMed
  6. Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D, Lamba J, Schuetz E, Donner DB, Puli N, Falck JR, Capdevila J, Gupta K, Blair IA, Potter DA. CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem. 2011 May 20; 286(20):17543-59. View in PubMed
  7. Lin CI, Du J, Shen WT, Whang EE, Donner DB, Griff N, He F, Moore FD, Clark OH, Ruan DT. Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab. 2011 Mar; 96(3):E554-65. View in PubMed
  8. Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, Jiang X, Price BD, Moore FD, Ruan DT. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res. 2010 Sep; 8(9):1217-26. View in PubMed
  9. Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res. 2010 Sep; 163(1):47-51. View in PubMed
  10. Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer. 2010 Mar; 17(1):283-91. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of David Donner, Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X